Early lung cancer screening (LCS) through low-dose computed tomography (LDCT) is crucial but underused due to various barriers, including incomplete or inaccurate patient smoking data in the electronic health record and limited time for shared decision-making. The objective of this trial is to investigate a patient-centered intervention, MyLungHealth, delivered through the patient portal. The intervention is designed to improve LCS rates through increased identification of eligible patients and informed decision making.
MyLungHealth is a multi-site pragmatic trial, involving University of Utah Health and New York University Langone Health primary care clinics. The MyLungHealth intervention was developed using a user-centered design process, informed by patient and provider focus groups and interviews. The intervention's effectiveness will be evaluated through a patient-randomized trial, comparing the combined use of MyLungHealth and DecisionPrecision+ (a provider-focused clinical decision support and shared decision-making intervention) against DecisionPrecision+ alone.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SCREENING
Masking
NONE
Enrollment
31,303
MyLungHealth is a patient-centered, EHR-integrated smoking data-quality improvement and education intervention. A key component of the MyLungHealth intervention is a pre-visit LCS eligibility questionnaire asked through the Epic EHR patient portal for individuals with unclear LCS eligibility due to missing or potentially inaccurate data in the EHR. Another key component of the MyLungHealth intervention is an interoperable, patient-centered educational app delivered through the EHR patient portal.
DecisionPrecision+ is a multi-faceted intervention which includes provider-facing EHR preventive care reminders, a provider-facing EHR SDM tool, and simple patient-facing preventive care reminders.
NYU Langone Health
New York, New York, United States
University of Utah Health
Salt Lake City, Utah, United States
Study 1 Primary Outcome: Count of Patients Newly Identified as Eligible for Lung Cancer Screening
In Study 1, the primary outcome was the number of patients newly identified as eligible for lung cancer screening during the 12-month follow-up period, defined as having a smoking history of at least 20 pack-years and being a current smoker or having quit within the past 15 years, based on structured electronic health record data and patient-reported smoking history collected through the MyLungHealth patient portal.
Time frame: 1 year trial period
Study 2 Primary Outcome: Count of Participants for Whom LDCT Was Ordered.
In Study 2, which enrolled participants with documented lung cancer screening eligibility at baseline, the primary outcome was the count of participants for whom a low-dose computed tomography (LDCT) lung cancer screening order was placed during the 12-month follow-up period, as identified from structured electronic health record order data.
Time frame: 1 year trial period
Study 1 Secondary Outcome: Count of Participants for Whom LDCT Eligibility Status Became Known.
In Study 1, which enrolled participants with uncertain lung cancer screening eligibility at baseline, a secondary outcome was the count of participants for whom lung cancer screening eligibility status became known during the 12-month follow-up period, based on structured electronic health record data and patient-reported smoking history collected through the MyLungHealth patient portal.
Time frame: 1 year trial period
Study 1 Secondary Outcome: Count of Participants for Whom LDCT Was Ordered.
Secondary outcomes for Study 1 will be the count of participants for whom LDCT was ordered during the 1-year trial.
Time frame: 1 year trial period
Study 1 Secondary Outcome: Count of Participants for Whom LDCT Was Completed.
Secondary outcomes for Study 1 will be the percentage of participants for whom LDCT was completed during the 1-year trial.
Time frame: 1 year trial period
Study 2 Secondary Outcome: Count of Participants for Whom LDCT Was Completed.
A secondary outcome for Study 2 will be the percentage of participants for whom LDCT was completed during the 1-year trial.
Time frame: 1 year trial period
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.